Awardee OrganizationCHILDREN'S HOSP OF PHILADELPHIA
Description
Abstract Text
DESCRIPTION (provided by applicant): Acquisition and maintenance of normal bone mass requires an adequate number of proliferative osteogenic precursor cells as well as the differentiated functions of osteoblasts. A reduction in the osteoblast precursor cell population or under-performing osteoblasts has been associated with abnormal development of the skeleton, as well as impaired bone remodeling and fracture healing in aging patients. Increasingly, it is being recognized that local factors, including fibroblast growth factors (FGFs), are crucial regulators of the cellular events associated with the osteogenic process. The bone-inducing effects of FGFs are mediated through four high affinity receptors (FgfR1-4), with FgfR1 and 2 being the major receptors expressed in bone. However the mechanisms of FGF's bone inducing effect as well as specific functions of each FgfR in osteogenesis remain elusive. In this study, we will test the hypothesis that temporally expressed FgfR1 and FgfR2 coordinates osteogenic cell proliferation and differentiation to promote bone growth. In developing bones, expression of FgfR2 is mainly restricted to highly proliferative osteoblast precursor cells and decreases with maturation. Concomitant with FgfR2 down-regulation, cell proliferation decreases and FgfR1 expression increases in differentiating osteoblasts. Collective data from our preliminary transgenic mouse and in vitro cell culture studies suggest that FgfR1 and FgfR2 both positively contribute to bone formation but may have differential roles in the regulation of bone cell proliferation and differentiation. The loss of FgfR2 and FgfR1 function results in drastically reduced intramembranous and trabecular bone mass in mice, while gain of FgfR2 function appears to stimulate bone formation. Our in vitro preliminary data suggest that FgfR2 stimulates cell proliferation but inhibits late differentiation and that Rtmx2, BMP-2 and Stat1 may be downstream mediators of FgfR2 functions. Therefore, we propose that FgfR2 plays a significant role in expanding the differentiation-competent early osteogenic cell population, by stimulating both cell proliferation and early osteogenic differentiation via increases in Runx2 and/or BMP-2 and phosphorylation of Stat1. We propose further that late osteogenic differentiation requires down-regulation of FgfR2 and perhaps also up-regulation ofFgfR1. Our hypothesis will be tested in a complementary set of in vitro and in vivo studies, utilizing transgenic and gene knock out approaches to selectively modulate either FgfR1 or FgfR2 activity.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
073757627
UEI
G7MQPLSUX1L4
Project Start Date
01-August-2004
Project End Date
31-July-2009
Budget Start Date
01-August-2006
Budget End Date
31-July-2007
Project Funding Information for 2006
Total Funding
$285,294
Direct Costs
$171,864
Indirect Costs
$113,430
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$285,294
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR050627-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR050627-04
Patents
No Patents information available for 5R01AR050627-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR050627-04
Clinical Studies
No Clinical Studies information available for 5R01AR050627-04
News and More
Related News Releases
No news release information available for 5R01AR050627-04
History
No Historical information available for 5R01AR050627-04
Similar Projects
No Similar Projects information available for 5R01AR050627-04